Plasma Cholinesterase Activity in Alzheimer's Disease
Authors:
- Koji HoriKHKoji Hori
- Kimiko KonishiKKKimiko Konishi
- Masayuki TaniMTMasayuki Tani
- Hiroi TomiokaHTHiroi Tomioka
- Yuka KitajimaYKYuka Kitajima
- Norihisa AkashiNANorihisa Akashi
- Atsuko InamotoAIAtsuko Inamoto
- Sousuke MinamiSMSousuke Minami
- Takuji IzunoTITakuji Izuno
- Kaori UmezawaKUKaori Umezawa
- Kentaro HoriuchiKHKentaro Horiuchi
- 1 June 2015
- journal article
- review article
- Published by S. Karger AG in Neurodegenerative Diseases
- Vol. 15 (3) , 188-190
Abstract
Cholinesterase inhibitors (ChEIs) are not allowed to be prescribed in combination, which means that we need to select 1 of 3 ChEIs for use in a patient with Alzheimer's disease (AD). However, there is no quantitative analysis on the differences between these agents. In this article, we propose that plasma cholinesterase activity (pChE) could be used as the standard for differentiating between rivastigmine (Riv) and donepezil (Don) in the management of AD. To date, we have treated 6 patients with Riv 18 mg and 5 patients with Don 5 mg. The pChE is related to low-grade inflammation associated with AD, diabetes mellitus and lipid metabolic dysfunction. Moreover, low pChE is related to liver dysfunction. The pChE must be kept under control. We speculated that Riv is the most appropriate therapy for patients with relatively high pChE, whereas Don is best reserved for those AD patients with relatively low pChE.Keywords
This publication has 13 references indexed in Scilit:
- Serum Anticholinergic Activity: A Possible Peripheral Marker of the Anticholinergic Burden in the Central Nervous System in Alzheimer’s DiseaseDisease Markers, 2014
- Serum cholinesterase is an excellent biomarker of liver cirrhosisTropical Gastroenterology, 2014
- Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: short- and long-term modification by non-genetic risk factorsFrontiers in Aging Neuroscience, 2013
- Targeting BuChE-inflammatory Pathway by SK0506 to Manage Type 2 Diabetes and Alzheimer DiseaseNeurochemical Research, 2009
- Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemiaProceedings of the National Academy of Sciences of the United States of America, 2006
- Inflammatory Proteins in Plasma and the Risk of DementiaArchives of Neurology, 2004
- Neurobiology of butyrylcholinesteraseNature Reviews Neuroscience, 2003
- Molecular and cellular biology of cholinesterasesProgress in Neurobiology, 1993
- Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.BMJ, 1978
- “Mini-mental state”Journal of Psychiatric Research, 1975